Gastro-oesophageal Reflux DiseasePhase 4NCT06664008
The Effect of Probiotic and Zinc Supplementation in Patients With Gastroesophageal Reflux Disease
A Phase 4 study testing PPI (proton pump inhibitor), Probiotic and Zinc in people with Gastro-oesophageal Reflux Disease, run by Ain Shams University.
Trial summary
Introduction: Gastroesophageal reflux disease (GERD) is a common digestive disorder affecting the esophagus and gastro-duodenum, presenting symptoms such as acid reflux and heartburn. GERD\'s incidence, symptoms, and prognosis are heavily influenced by diet and lifestyle factors. Read more about this study
- Who is it for?
- Ages 18 to 74 years
- Conditions the study is for
- Gastro-oesophageal Reflux Disease
- What is being tested?
- PPI (proton pump inhibitor), Probiotic and Zinc
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- No sites listed yet
- Study dates
- 1 Nov 2024to 1 Oct 2025
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 74 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18-74 years; (both male and female).
- Esophagitis that might be confirmed by gastroscopy.
- Patients with confirmed symptoms of GERD N.B.: The typical clinical presentation of GERD is heartburn and regurgitation. Heartburn is defined as a retrosternal burning sensation or discomfort that may radiate into the neck and typically occurs after the ingestion of meals or when in a reclined position. Regurgitation is a retrograde migration of acidic gastric contents into the mouth or hypopharynx . GERD can also present with various other symptoms that include dysphagia, odynophagia, belching, epigastric pain, and nausea.
Who cannot join
- Allergy or potential allergy to the study medications.
- Pregnancy.
- Patients with CrCl\< 20 ml/min or on dialysis.
- Patients with myocardial infarction, stroke, or malignant tumour.
- Patients with liver insufficiency (liver enzymes \> 2*upper limit of normal)
- Heart Failure or ECG (electrocardiogram) abnormalities
- Gastroscopy that revealed any of the following diseases within the last 2 months: bleeding, esophageal and gastric varices, upper gastrointestinal malignant lesions.
- A history of gastroesophageal or duodenal surgery.
Trial locations and contacts
No sites are listed yet.
About this study
Introduction:
Gastroesophageal reflux disease (GERD) is a common digestive disorder affecting the esophagus and gastro-duodenum, presenting symptoms such as acid reflux and heartburn. GERD\'s incidence, symptoms, and prognosis are heavily influenced by diet and lifestyle factors. Current management of GERD involves lifestyle modifications (e.g., weight loss, dietary changes) and pharmacologic agents like proton pump inhibitors (PPIs), histamine-2-receptor blockers (H2 B), antacids, and medications that affect gastrointestinal motility (Kröner et al., 2021).
Read more
Background on Probiotics and Zinc:
Probiotics are non-pathogenic microorganisms that, when administered in adequate amounts, offer several health benefits, including improvement in conditions associated with inflammation and gut health. Probiotics, often of the Lactobacillusand Bifidobacterium species, interact with gut microbiota, enhance barrier function, and modulate immune responses (Cheng \& Ouwehand, 2020; Kröner et al., 2021). Probiotics have been linked to reduced levels of inflammatory mediators, such as cytokines, and are recognized for their anti-inflammatory and antioxidant properties (Sharifi-Rad et al., 2020; Wang et al., 2017).
Zinc, specifically Zinc L-carnosine, exhibits antioxidant, cytokine modulation, and membrane-stabilizing properties, acting as a mucosal cytoprotective and anti-inflammatory agent (Efthymakis \& Neri, 2022). Previous studies suggest that the combination of probiotics and zinc may be beneficial for gut health, but there is limited data on their effects on GERD symptoms, inflammation, and oxidative stress.
Study Aim:
To evaluate the effect of probiotics and zinc on GERD symptoms and to explore their potential antioxidant and anti-inflammatory effects.
Patients and Methods:
Study Design:
This is a prospective controlled randomized comparative study conducted at El-Demerdash Hospital, Ain Shams University Hospitals.
Ethical Considerations:
The study has received ethical approval from the Research Ethics Committee of the Faculty of Pharmacy, Ain Shams University, and the Scientific Research Ethics Committee at the Faculty of Medicine, Ain Shams University. It adheres to the Declaration of Helsinki and is registered on ClinicalTrials.gov.
Participants:
Inclusion Criteria: Adults aged 18-74 years with esophagitis confirmed by gastroscopy and GERD symptoms.
Exclusion Criteria: Allergy to study medications, pregnancy, severe renal or liver insufficiency, history of myocardial infarction, stroke, malignant tumors, and certain gastrointestinal conditions or surgeries.
Sample Size Calculation:
The study is designed to detect a large effect size (f = 0.4) for zinc and probiotic effects using G*Power software. A total of 120 patients will be recruited (30 per group) to account for a 15% dropout rate.
Study Groups:
Group I (Control): PPI (Omeprazole 40 mg daily). Group II: PPI + probiotic. Group III: PPI + zinc. Group IV: PPI + probiotic and zinc.
Methodology:
Participants will undergo baseline assessments, including medical history, gastroscopy, and measurement of gastrointestinal hormones, inflammatory markers (IL-6, IL-12, CRP), and oxidative stress markers (MDA). The same assessments will be repeated at the study\'s end after 4 weeks. Follow-up assessments will occur biweekly, and patients will be contacted between visits to monitor side effects.
Outcomes:
Primary Outcome: Change in Gastrointestinal Symptom Rating Scale (GSRS) scores and gastrin hormone levels before and after treatment.
Secondary Outcomes:
Anti-inflammatory effect (IL-6, IL-12, CRP levels). Antioxidant effect (MDA levels).
Statistical Analysis:
Data will be analyzed using SPSS. Statistical significance is set at p ≤ 0.05. Continuous variables will be expressed as mean ± SD or median (interquartile range), depending on distribution, and analyzed using appropriate tests (e.g., T-test or Mann-Whitney U test).
This study aims to provide insights into the potential benefits of probiotics and zinc in managing GERD symptoms and their anti-inflammatory and antioxidant effects, filling a current gap in the literature.
- Conditions
- Gastro-oesophageal Reflux Disease
- Being tested
- PPI (proton pump inhibitor), Probiotic, Zinc
- Medical subject headings
- Gastroesophageal Reflux
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PPI (proton pump inhibitor)Drug
It reduces stomach acid production and manage GERD symptoms
ProbioticDrug
Live microorganisms, primarily bacteria and yeast, that are believed to provide health benefits when consumed in adequate.
ZincDrug
Zinc used a supplement due to its role in decreasing inflammation of the gastroesophageal reflux disease.
| Study group | Role | What they receive |
|---|---|---|
| Group 1: PPI alone | Active comparator | Proton pump inhibitor Receives: Drug: PPI (proton pump inhibitor) |
| Group 2 (PPI+Probiotic) | Experimental | Proton pump inhibitor and Probiotic Receives: Drug: PPI (proton pump inhibitor); Drug: Probiotic |
| Group 3: PPI+Zinc | Experimental | Proton pump inhibitor and Zinc Receives: Drug: PPI (proton pump inhibitor); Drug: Zinc |
| Group 4: PPI+Probiotic and Zinc | Experimental | Proton pump inhibitor, Zinc and Probiotic Receives: Drug: PPI (proton pump inhibitor); Drug: Probiotic; Drug: Zinc |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Gastrointestinal Symptom Rating Scale (GSRS)
•The primary efficacy variable will be the change in Gastrointestinal Symptom Rating Scale (GSRS) score before and after treatment (reflecting the patient's experience of the dyspepsia symptoms during the preceding weeks: pain, heartburn, acid reflux, hunger, pain, nausea, stomach rumbles, stomach swelling, belching, bloating, constipation, diarrhea, and interchange between constipation and diarrhea) as well as the effect on gastrin hormone level.
Measured: 1 month
Secondary outcomes (2)
Anti-inflammatory effect will be measured through the markers (Interleukin-6 (IL-6), Interleukin-12 (IL-12) and CRP levels.
Measured: 1 month
Antioxidant effect measured through oxidative stress marker as (MAD).
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Oct 2024
- Study start1 Nov 2024 (estimated)
- Primary completion1 Mar 2025 (estimated)
- Study completion1 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastro-oesophageal Reflux DiseaseStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Christina Medhat, British University In Egypt
- Investigators
- Nagwa A Sabri, Study director, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06664008
- Sponsor's protocol ID
- FMASUR200/2024
- Status last verified
- Oct 2024
- First submitted
- 27 Oct 2024
- Last updated
- 29 Oct 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Probiotic and Zinc Supplementation in Patients With Gastroesophageal Reflux Disease
- ClinicalTrials.gov ID
- NCT06664008
- Acronym / sponsor ID
- FMASUR200/2024
- Conditions
- Gastro-oesophageal Reflux Disease
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 1 Nov 2024 (estimated)
- Primary completion
- 1 Mar 2025 (estimated)
- Study completion
- 1 Oct 2025 (estimated)
- First posted
- 29 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction:
Gastroesophageal reflux disease (GERD) is a common digestive disorder affecting the esophagus and gastro-duodenum, presenting symptoms such as acid reflux and heartburn. GERD\'s incidence, symptoms, and prognosis are heavily influenced by diet and lifestyle factors. Current management of GERD involves lifestyle modifications (e.g., weight loss, dietary changes) and pharmacologic agents like proton pump inhibitors (PPIs), histamine-2-receptor blockers (H2 B), antacids, and medications that affect gastrointestinal motility (Kröner et al., 2021).
Background on Probiotics and Zinc:
Probiotics are non-pathogenic microorganisms that, when administered in adequate amounts, offer several health benefits, including improvement in conditions associated with inflammation and gut health. Probiotics, often of the Lactobacillusand Bifidobacterium species, interact with gut microbiota, enhance barrier function, and modulate immune responses (Cheng \& Ouwehand, 2020; Kröner et al., 2021). Probiotics have been linked to reduced levels of inflammatory mediators, such as cytokines, and are recognized for their anti-inflammatory and antioxidant properties (Sharifi-Rad et al., 2020; Wang et al., 2017).
Zinc, specifically Zinc L-carnosine, exhibits antioxidant, cytokine modulation, and membrane-stabilizing properties, acting as a mucosal cytoprotective and anti-inflammatory agent (Efthymakis \& Neri, 2022). Previous studies suggest that the combination of probiotics and zinc may be beneficial for gut health, but there is limited data on their effects on GERD symptoms, inflammation, and oxidative stress.
Study Aim:
To evaluate the effect of probiotics and zinc on GERD symptoms and to explore their potential antioxidant and anti-inflammatory effects.
Patients and Methods:
Study Design:
This is a prospective controlled randomized comparative study conducted at El-Demerdash Hospital, Ain Shams University Hospitals.
Ethical Considerations:
The study has received ethical approval from the Research Ethics Committee of the Faculty of Pharmacy, Ain Shams University, and the Scientific Research Ethics Committee at the Faculty of Medicine, Ain Shams University. It adheres to the Declaration of Helsinki and is registered on ClinicalTrials.gov.
Participants:
Inclusion Criteria: Adults aged 18-74 years with esophagitis confirmed by gastroscopy and GERD symptoms.
Exclusion Criteria: Allergy to study medications, pregnancy, severe renal or liver insufficiency, history of myocardial infarction, stroke, malignant tumors, and certain gastrointestinal conditions or surgeries.
Sample Size Calculation:
The study is designed to detect a large effect size (f = 0.4) for zinc and probiotic effects using G*Power software. A total of 120 patients will be recruited (30 per group) to account for a 15% dropout rate.
Study Groups:
Group I (Control): PPI (Omeprazole 40 mg daily). Group II: PPI + probiotic. Group III: PPI + zinc. Group IV: PPI + probiotic and zinc.
Methodology:
Participants will undergo baseline assessments, including medical history, gastroscopy, and measurement of gastrointestinal hormones, inflammatory markers (IL-6, IL-12, CRP), and oxidative stress markers (MDA). The same assessments will be repeated at the study\'s end after 4 weeks. Follow-up assessments will occur biweekly, and patients will be contacted between visits to monitor side effects.
Outcomes:
Primary Outcome: Change in Gastrointestinal Symptom Rating Scale (GSRS) scores and gastrin hormone levels before and after treatment.
Secondary Outcomes:
Anti-inflammatory effect (IL-6, IL-12, CRP levels). Antioxidant effect (MDA levels).
Statistical Analysis:
Data will be analyzed using SPSS. Statistical significance is set at p ≤ 0.05. Continuous variables will be expressed as mean ± SD or median (interquartile range), depending on distribution, and analyzed using appropriate tests (e.g., T-test or Mann-Whitney U test).
This study aims to provide insights into the potential benefits of probiotics and zinc in managing GERD symptoms and their anti-inflammatory and antioxidant effects, filling a current gap in the literature.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Group 1: PPI alone | Active comparator | Drug: PPI (proton pump inhibitor)Proton pump inhibitor |
| Group 2 (PPI+Probiotic) | Experimental | Drug: PPI (proton pump inhibitor), Drug: ProbioticProton pump inhibitor and Probiotic |
| Group 3: PPI+Zinc | Experimental | Drug: PPI (proton pump inhibitor), Drug: ZincProton pump inhibitor and Zinc |
| Group 4: PPI+Probiotic and Zinc | Experimental | Drug: PPI (proton pump inhibitor), Drug: Probiotic, Drug: ZincProton pump inhibitor, Zinc and Probiotic |
Who may qualify
- Ages
- 18 to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults aged 18-74 years; (both male and female).
- Esophagitis that might be confirmed by gastroscopy.
- Patients with confirmed symptoms of GERD N.B.: The typical clinical presentation of GERD is heartburn and regurgitation. Heartburn is defined as a retrosternal burning sensation or discomfort that may radiate into the neck and typically occurs after the ingestion of meals or when in a reclined position. Regurgitation is a retrograde migration of acidic gastric contents into the mouth or hypopharynx . GERD can also present with various other symptoms that include dysphagia, odynophagia, belching, epigastric pain, and nausea.
Key exclusion criteria (8 listed)
- Allergy or potential allergy to the study medications.
- Pregnancy.
- Patients with CrCl\< 20 ml/min or on dialysis.
- Patients with myocardial infarction, stroke, or malignant tumour.
- Patients with liver insufficiency (liver enzymes \> 2*upper limit of normal)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PPI (proton pump inhibitor)It reduces stomach acid production and manage GERD symptoms | Drug | Group 1: PPI alone, Group 2 (PPI+Probiotic), Group 3: PPI+Zinc, Group 4: PPI+Probiotic and Zinc |
| ProbioticLive microorganisms, primarily bacteria and yeast, that are believed to provide health benefits when consumed in adequate. | Drug | Group 2 (PPI+Probiotic), Group 4: PPI+Probiotic and Zinc |
| ZincZinc used a supplement due to its role in decreasing inflammation of the gastroesophageal reflux disease. | Drug | Group 3: PPI+Zinc, Group 4: PPI+Probiotic and Zinc |
Primary outcome
Change in Gastrointestinal Symptom Rating Scale (GSRS)
Time frame: 1 month
•The primary efficacy variable will be the change in Gastrointestinal Symptom Rating Scale (GSRS) score before and after treatment (reflecting the patient's experience of the dyspepsia symptoms during the preceding weeks: pain, heartburn, acid reflux, hunger, pain, nausea, stomach rumbles, stomach swelling, belching, bloating, constipation, diarrhea, and interchange between constipation and diarrhea) as well as the effect on gastrin hormone level.
2 secondary outcomes
Anti-inflammatory effect will be measured through the markers (Interleukin-6 (IL-6), Interleukin-12 (IL-12) and CRP levels.
Time frame: 1 month
Antioxidant effect measured through oxidative stress marker as (MAD).
Time frame: 1 month
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2024.
- Individual participant dataSharing planned: Yes
Related trials for Gastro-oesophageal Reflux Disease
Not yet recruitingPhase 4
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Obese Adults
Recruiting
SPADE Clinical Trial.
Early Gastric Cancer, Adenocarcinoma of the Stomach
Enrolling by invitation
Endoscopic Treatment of Gastroesophageal Reflux Disease
Gastro Esophageal Reflux Disease
Enrolling by invitationObservational study
Assessment of Esophageal Epithelium Integrity With Use of a Novel Mucosal Impedance Device
Gastro Esophageal Reflux
Not yet recruitingPhase 4
PPI Dosing Per CYP2C19 Genotype
Gastroesophageal Reflux Disease With Esophagitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nagwa A Sabri study director
Ain Shams University
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing PPI (proton pump inhibitor), Probiotic and Zinc in people with Gastro-oesophageal Reflux Disease, run by Ain Shams University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 29 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Christina M Aziz (+201286750660, christina.medhat@bue.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Gastrointestinal Symptom Rating Scale (GSRS) (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2024.